Inicio4507 • TYO
add
Shionogi & Co Ltd
Cierre anterior
2059,00 ¥
Intervalo diario
2062,50 ¥ - 2109,50 ¥
Intervalo anual
1944,66 ¥ - 2712,33 ¥
Cap. bursátil
1,86 B JPY
Volumen medio
2,61 M
Relación precio-beneficio
11,59
Rentabilidad por dividendo
2,71 %
Bolsa de valores principal
TYO
Noticias sobre los mercados
Datos financieros
Estado de resultados
Ingresos
Ingresos netos
(JPY) | sept 2024info | Cambio interanual |
---|---|---|
Ingresos | 116,38 mil M | -4,00 % |
Gastos operativos | 52,93 mil M | -3,66 % |
Ingresos netos | 52,50 mil M | 9,30 % |
Margen de beneficio neto | 45,11 | 13,86 % |
Beneficios por acción | — | — |
EBITDA | 53,13 mil M | -5,14 % |
Tipo impositivo efectivo | 8,28 % | — |
Balance general
Activos totales
Responsabilidades totales
(JPY) | sept 2024info | Cambio interanual |
---|---|---|
Efectivo y a corto plazo | 303,40 mil M | 20,22 % |
Activos totales | 1,46 B | 3,34 % |
Responsabilidades totales | 145,93 mil M | -18,09 % |
Patrimonio total | 1,31 B | — |
Acciones en circulación | 850,69 M | — |
Precio-valor contable | 1,23 | — |
Rentabilidad económica | 8,22 % | — |
Retorno sobre capital | 9,10 % | — |
Flujo de caja
Variación neta del flujo de caja
(JPY) | sept 2024info | Cambio interanual |
---|---|---|
Ingresos netos | 52,50 mil M | 9,30 % |
Efectivo de operaciones | 45,30 mil M | 220,14 % |
Efectivo de inversión | -17,63 mil M | 47,30 % |
Efectivo de financiación | -1113,00 M | 94,50 % |
Variación neta del flujo de caja | 21,45 mil M | 158,43 % |
Flujo de caja libre | 8021,00 M | 135,46 % |
Información sobre la empresa
Shionogi & Company, Limited is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana.
Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines.
In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough to become a sole marketing agent for its products in Japan.
Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV.
The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index.
In June 2023, Shionogi announced its acquisition of Qpex Biopharma for approximately $140m. Wikipedia
Director ejecutivo
Fundación
1878
Sitio web
Empleados
4.959